A Pilot Study of Omalizumab to Treat Severe Allergic Asthma in South Indian Population
Abstract
Background: Asthma is a respiratory disease that affects your lungs. In asthma, airways of the lungs constrict due to swelling and accumulation of mucus. Newer remedies known as targeted therapies have evolved as a result of advancements in medical research, greatly relieving these patients. The biologics used in the severe allergic asthma is Omalizumab.
Purpose: Demonstrating the clinical efficacy of Omalizumab in severe allergic asthma by reducing exacerbation rates and increasing quality of life.
Methods: A single-arm prospective pilot study of omalizumab in severe allergic asthma was conducted in a tertiary care hospital for the duration of one year with the help of Asthma Quality of Life Questionnaire (AQLQ).
Results and discussions: On an initial dose of omalizumab of 150 mg in 2 vials subcutaneously every month for 6 months, among our study population, 45% of the patients had their symptoms improve more than they had with prior medications. Results show that the patient's overall score has improved by nearly 50%. This shows that omalizumab improves the quality of life of severe asthmatic patients.
Conclusion: Patients treated with omalizumab have improved their clinical conditions and quality of life, and it can prevent exacerbations by controlling the severity of the condition.
Keywords: AQLQ, Allergic asthma, Exacerbation, IgE, Omalizumab.
Keywords:
AQLQ, Allergic asthma, Exacerbation, IgE, OmalizumabDOI
https://doi.org/10.22270/jddt.v12i6-S.5855References
Astrazeneca.in. [cited 2022 Oct 11]. Available from: https://www.astrazeneca.in/content/dam/az-in/pdf/PDF/Asthma/Types%20of%20Asthma.pdf
India State-Level Disease Burden Initiative CRD Collaborators. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health [Internet]. 2018; 6(12):e1363–74. Available from: http://dx.doi.org/10.1016/S2214-109X(18)30409-1
Singh S, Sharma BB, Sharma SK, Sabir M, Singh V, ISAAC collaborating investigators. Prevalence and severity of asthma among Indian school children aged between 6 and 14 years: associations with parental smoking and traffic pollution. J Asthma [Internet]. 2016; 53(3):238–44. Available from: http://dx.doi.org/10.3109/02770903.2015.1087558
Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis [Internet]. 2012; 16(9):1270–7. Available from: http://dx.doi.org/10.5588/ijtld.12.0005
Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, et al. Prevalence, time trends and treatment practices of asthma in India: the Global Asthma Network study. ERJ Open Res [Internet]. 2022; 8(2):00528–2021. Available from: http://dx.doi.org/10.1183/23120541.00528-2021
CDC. Asthma [Internet]. Centers for Disease Control and Prevention. 2022 [cited 2022 Oct 11]. Available from: https://www.cdc.gov/asthma/default.htm
Loureiro CC, Amaral L, Ferreira JA, Lima R, Pardal C, Fernandes I, et al. Omalizumab for severe asthma: Beyond allergic asthma. Biomed Res Int [Internet]. 2018 [cited 2022 Oct 11]; 2018:3254094. Available from: https://www.hindawi.com/journals/bmri/2018/3254094/
Godse K, Mehta A, Patil S, Gautam M, Nadkarni N. Omalizumab-A review. Indian J Dermatol [Internet]. 2015 [cited 2022 Oct 14];60(4):381–4. Available from: http://dx.doi.org/10.4103/0019-5154.160490
Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy [Internet]. 2017 [cited 2022 Oct 14]; 72(4):519–33. Available from: http://dx.doi.org/10.1111/all.13083
Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial: A randomized trial. Ann Intern Med [Internet]. 2011; 154(9):573–82. Available from: http://dx.doi.org/10.7326/0003-4819-154-9-201105030-00002
Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma [Internet]. 2013 [cited 2022 Nov 19]; 50(5):529–36. Available from: https://pubmed.ncbi.nlm.nih.gov/23574000/
Published
Abstract Display: 754 
PDF Downloads: 494 PDF Downloads: 22 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.